Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD – Get Free Report) was the recipient of a large increase in short interest during the month of July. As of July 15th, there was short interest totalling 9,000 shares, an increase of 1,185.7% from the June 30th total of 700 shares. Currently, 0.2% of the company’s stock are sold short. Based on an average daily volume of 58,000 shares, the short-interest ratio is presently 0.2 days.
Wall Street Analysts Forecast Growth
Separately, StockNews.com assumed coverage on Galmed Pharmaceuticals in a research note on Sunday, July 21st. They set a “sell” rating on the stock.
Get Our Latest Stock Analysis on GLMD
Galmed Pharmaceuticals Price Performance
Galmed Pharmaceuticals (NASDAQ:GLMD – Get Free Report) last posted its earnings results on Thursday, May 30th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter.
About Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.
See Also
- Five stocks we like better than Galmed Pharmaceuticals
- What is the Euro STOXX 50 Index?
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
- What is a Stock Market Index and How Do You Use Them?
- Skechers Stock Shows Strength Among Consumer Discretionary Sector
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Tech Stocks Tumble, These Stocks Present Buying Opportunity
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.